Cardiologia

Podcast | Domine a angina estável com os CardioNerds.

15 Jun, 2021 | 11:12h

#279 Dominate Stable Angina with the CardioNerds – The Curbsiders

OMS: mais de 100 motivos para abandonar o tabaco.

14 Jun, 2021 | 11:08h

More than 100 reasons to quit tobacco – World Health Organization

Comentário no Twitter (fio – clique para saber mais)

Quitting tobacco 🚭 can be challenging but there are more than 💯 reasons to #CommitToQuit & start living a healthier life.

Find out more 👉https://t.co/8uBEMvH0cu pic.twitter.com/iwrt86xSVo

— World Health Organization (WHO) (@WHO) June 13, 2021

M-A | Efeitos de betabloqueadores de ação ultracurta na mortalidade de pacientes com sepse e taquicardia persistente.

14 Jun, 2021 | 11:04h

Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trials – CHEST

Consenso da ESC | Lesão miocárdica periprocedimento e infarto associado a intervenções coronarianas percutâneas.

14 Jun, 2021 | 11:03h

Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI) – European Heart Journal

Comentários: Periprocedural MIs Associated With PCI Prognostically Relevant: ESC/EAPCI – TCTMD E Periprocedural Myocardial Injury and MI Associated With PCI – American College of Cardiology

CDC afirma que casos de inflamação cardíaca em pessoas de 16 a 24 anos depois da segunda dose da vacina contra Covid foram acima do esperado, mas, ainda assim, raros.

11 Jun, 2021 | 10:42h

CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare – CNBC

Ver também: CDC plans “emergency meeting” on rare heart inflammation following COVID-19 vaccines – CBC News

Relacionado: Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men.

Estudo randomizado | Em pacientes com fibrilação atrial ou valvas cardíacas mecânicas, tratados com warfarina e submetidos à cirurgia, o tratamento pós-operatório com “ponte” (bridging treatment) de heparina de baixo peso molecular não evitou tromboembolismo maior.

11 Jun, 2021 | 10:33h

Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial – The BMJ

Comentário no Twitter

P-E-R-S-E-V-E-R-A-N-C-E = 15 yrs from start to BMJ publication. Bottom line: in pts with atrial fibrillation or mechanical heart valves who had warfarin interrupted for a procedure, we found no benefit of
postop LMWH bridging to prevent major
thromboembolism @canvector @CIHR_ICRH https://t.co/9z0XTQgsbA

— Susan R Kahn (@SusanRKahn1) June 10, 2021

Drogas antiarrítmicas para fibrilação atrial no paciente ambulatorial: cenários clínicos comuns e dicas para o médico da atenção primária.

11 Jun, 2021 | 10:32h

Antiarrhythmic Drugs for Atrial Fibrillation in the Outpatient Setting: Common Clinical Scenarios and Pearls for the Primary Care Clinician – Mayo Clinic Proceedings

Mais dados sugerem que não há benefício cardiovascular na suplementação de ômega 3 – Análise secundária do estudo STRENGHT não mostrou associação entre os níveis atingidos de ácido graxo ômega 3 e desfechos cardiovasculares adversos maiores em pacientes com alto risco cardiovascular.

8 Jun, 2021 | 10:20h

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial – JAMA Cardiology

Estudo original: #AHA20 – Randomized trial: High-dose Omega-3 fatty acids did not reduce the risk of cardiac events in patients at high cardiovascular risk

Comentários: Higher blood levels of omega-3 fatty acids from prescription fish oil showed no effect on CV events – American College of Cardiology

Estudo randomizado | Drogas protetoras cardíacas parecem ser desnecessárias para a maioria das pacientes com câncer de mama submetidas a tratamento adjuvante.

8 Jun, 2021 | 10:17h

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol – Circulation

Comentários: Heart-protecting drugs likely unnecessary for many breast cancer patients – American College of Cardiology

Revisão | Conduta em pacientes com tromboembolismo venoso após o período inicial de tratamento.

8 Jun, 2021 | 10:16h

Management of Patients With Venous Thromboembolism After the Initial Treatment Period – The Journal of the American Board of Family Medicine